What is GRI's last price and market cap on Chartloom?

The overview shows a last price near n/a and market cap near 0.00B (subject to data latency), alongside the price snapshot and profile on this page.

What P/E and 52-week range are shown for GRI?

P/E (TTM) is n/a and 52-week range is $1.36 to $64.12 when available from the data feed; see the metrics and chart on this page.

Where do Chartloom’s GRI figures come from?

Figures are compiled from market data and SEC-backed fundamentals used in the app. Use primary filings and a broker for trading decisions.

What trailing-twelve-month financials does Chartloom show for GRI?

The company profile lists net income (TTM) near $-91M, EPS (TTM) near $-51.65 when available from the market-data feed. Figures are informational and may lag live markets.

Where is GRI Bio Inc based, and what identifiers does Chartloom list?

The company context section lists headquarters in La Jolla, California, US, 1.8M shares outstanding, ISIN US3622AW5029 when available from company profile and filing metadata.

GRI Bio Inc

$GRI

Health Care · Biotechnology

IR Run Scenarios

$1.74

+3.57%

Overview AI Summary Charts Financials Valuation

Profile

Read AI summary

GRI Bio, Inc. engages in the development and commercialization of therapies for inflammatory, fibrotic, and autoimmune diseases. The company is headquartered in La Jolla, California and currently employs 4 full-time employees. The company went IPO on 2021-02-10. The Company’s therapies are designed to target the activity of Natural Killer T (NKT) cells, which are key regulators earlier in the inflammatory cascade, to interrupt disease progression and restore the immune system to homeostasis. Its lead program, GRI-0621, is an inhibitor of iNKT cell activity and is being developed as a novel oral therapeutic for the treatment of idiopathic pulmonary fibrosis. The firm is also developing a pipeline of novel type II diverse NKT agonists for the treatment of systemic lupus erythematosus. Its product candidate portfolio also includes GRI-0803 and a proprietary library of more than 500 compounds. The company is developing GRI-0803 for the treatment of autoimmune disorders, with much of its preclinical work in systemic lupus erythematosus disease (SLE) and multiple sclerosis (MS).

Employees

Website

www.gribio.com/

IPO

2021-02-10

Beta

Next earnings date

—

Financials & valuation

Open valuation

Revenue (TTM)

Net income (TTM)